Literature DB >> 23576010

[Fungal infections in hematology patients and after blood stem cell transplantation: prophylaxis and treatment].

G Egerer1, T Schmitt.   

Abstract

Patients with prolonged neutropenia or immunosuppression after stem cell transplantation are at a high risk of developing invasive fungal infections. Antimycotic prophylaxis is used to reduce the associated morbidity and mortality. The following classes of antimycotic agents are currently available: azoles (e.g., fluconazole, itraconazole, posaconazole), echinocandins (caspofungin, micafungin), and amphotericin B.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23576010     DOI： 10.1007/s00063-013-0238-y

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


  23 in total

1.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

2.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

3.  An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.

Authors:  Axel Glasmacher; Oliver Cornely; Andrew J Ullmann; Ulrich Wedding; Heinrich Bodenstein; Hannes Wandt; Christian Boewer; Rita Pasold; Hans-Heinrich Wolf; Mathias Hänel; Gottfried Dölken; Christian Junghanss; Reinhard Andreesen; Hartmut Bertz
Journal:  J Antimicrob Chemother       Date:  2005-12-08       Impact factor: 5.790

4.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

5.  High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  J El-Cheikh; C Faucher; S Fürst; S Duran; P Berger; N Vey; A-M Stoppa; R Bouabdallah; J-A Gastaut; P Viens; D Blaise; M Mohty
Journal:  Bone Marrow Transplant       Date:  2007-01-29       Impact factor: 5.483

6.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.

Authors:  J Maertens; O Marchetti; R Herbrecht; O A Cornely; U Flückiger; P Frêre; B Gachot; W J Heinz; C Lass-Flörl; P Ribaud; A Thiebaut; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

7.  Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

Authors:  Catherine Cordonnier; Cécile Pautas; Sébastien Maury; Anne Vekhoff; Hassan Farhat; Felipe Suarez; Nathalie Dhédin; Francoise Isnard; Lionel Ades; Frédérique Kuhnowski; Françoise Foulet; Mathieu Kuentz; Patrick Maison; Stéphane Bretagne; Michaël Schwarzinger
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

8.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

Authors:  M A Slavin; B Osborne; R Adams; M J Levenstein; H G Schoch; A R Feldman; J D Meyers; R A Bowden
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.

Authors:  Satoshi Hashino; Lena Morita; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-12-11       Impact factor: 2.319
View more
  1 in total

1.  Does galactomannan testing increase diagnostic accuracy for IPA in the ICU? A prospective observational study.

Authors:  Maria Schroeder; Marcel Simon; Juri Katchanov; Charles Wijaya; Holger Rohde; Martin Christner; Azien Laqmani; Dominic Wichmann; Valentin Fuhrmann; Stefan Kluge
Journal:  Crit Care       Date:  2016-05-10       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.